PMID- 20358868
OWN - NLM
STAT- MEDLINE
DCOM- 20100503
LR  - 20181201
IS  - 0019-5189 (Print)
IS  - 0019-5189 (Linking)
VI  - 48
IP  - 1
DP  - 2010 Jan
TI  - Role of glucagon-like peptide- 1 in vascular endothelial dysfunction.
PG  - 61-9
AB  - The present study has been undertaken to investigate the effect of exendin-4 (a 
      glucagon-like peptide-1 agonist) in diabetes mellitus (DM) and 
      hyperhomocysteinemia (HHcy)-induced vascular endothelial dysfunction (VED). 
      Streptozotocin (55 mg kg-1, iv, once) and methionine (1.7% w/w, po, 4 weeks) were 
      administered to rats to produce DM (serum glucose >200 mg d1-1) and HHcy (serum 
      homocysteine >10 microM) respectively. VED was assessed using isolated aortic 
      ring preparation, microscopy of thoracic aorta, and serum nitrite/nitrate 
      concentration. Serum TBARS concentration was estimated to assess oxidative 
      stress. Atorvastatin has been employed as standard agent. Exendin-4 (1 microg 
      kg-1, ip) and atorvastatin (30 mg kg-1, po) treatments significantly attenuated 
      increase in serum glucose and homocysteine but their concentrations remained 
      markedly higher than sham control value. Exendin-4 and atorvastatin treatments 
      markedly prevented DM and HHcy-induced (i) attenuation of acetylcholine-induced 
      endothelium-dependent relaxation, (ii) impairment of vascular endothelial lining, 
      (iii) decrease in serum nitrite/nitrate concentration, and (iv) increase in serum 
      TBARS. However, this ameliorative effect of exendin-4 has been prevented by 
      L-NAME (25 mg kg-1, ip), an inhibitor of NOS. It may be concluded that exendin-4 
      may activate eNOS due to activation of GLP-1 and consequently reduce oxidative 
      stress to improve vascular endothelial dysfunction.
FAU - Goyal, Sandeep
AU  - Goyal S
AD  - Department of Pharmacology, S D College of Pharmacy, Barnala 148 101, India. 
      sangoyal2007@rediffmail.com
FAU - Kumar, Suresh
AU  - Kumar S
FAU - Bijjem, Krishnareddy V
AU  - Bijjem KV
FAU - Singh, Manjeet
AU  - Singh M
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
RN  - 0 (Heptanoic Acids)
RN  - 0 (Peptides)
RN  - 0 (Pyrroles)
RN  - 0 (Venoms)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9P1872D4OL (Exenatide)
RN  - A0JWA85V8F (Atorvastatin)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 1.14.13.39 (Nos3 protein, rat)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Animals
MH  - Atorvastatin
MH  - Diabetes Mellitus, Experimental/pathology/physiopathology
MH  - Endothelium, Vascular/drug effects/pathology/*physiopathology
MH  - Exenatide
MH  - Female
MH  - Glucagon-Like Peptide 1/agonists/*physiology
MH  - Heptanoic Acids/pharmacology
MH  - Hyperhomocysteinemia/pathology/physiopathology
MH  - In Vitro Techniques
MH  - Male
MH  - NG-Nitroarginine Methyl Ester/pharmacology
MH  - Nitric Oxide Synthase Type III/antagonists & inhibitors/physiology
MH  - Peptides/pharmacology
MH  - Pyrroles/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Venoms/pharmacology
EDAT- 2010/04/03 06:00
MHDA- 2010/05/04 06:00
CRDT- 2010/04/03 06:00
PHST- 2010/04/03 06:00 [entrez]
PHST- 2010/04/03 06:00 [pubmed]
PHST- 2010/05/04 06:00 [medline]
PST - ppublish
SO  - Indian J Exp Biol. 2010 Jan;48(1):61-9.